128 results on '"Pusic, Iskra"'
Search Results
2. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002
3. Acute Graft-versus-Host Disease: An Update on New Treatment Options
4. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans
5. Germinal centre-driven maturation of B cell response to mRNA vaccination
6. How to utilize current guidelines to manage patients with cancer at high risk for heart failure.
7. Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival
8. Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS
9. Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation
10. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
11. CML and the WHO: Why?
12. Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease
13. Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD
14. CML and the WHO: Why?
15. 45. Clonal hematopoiesis in childhood cancer survivors
16. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality
17. Clonal hematopoiesis in survivors of childhood cancer
18. Patient-reported treatment response in chronic graft-versus-host disease
19. Abstract 4342: Predictive precision medicine platform accurately predicts individual patient response to AML treatments to maximize outcomes
20. Data from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
21. Supplementary Tables from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
22. Supplementary Methods from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
23. Supplementary Figures from Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
24. supplemental figure legend from A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation
25. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study
26. Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant
27. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans
28. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.
29. Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy
30. Patient-Reported Treatment Response in Chronic Graft Vs. Host Disease: Unique Dimension of Clinical Benefit Associated with Failure-Free Survival
31. A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
32. Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease
33. Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment
34. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy
35. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
36. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study
37. Lessons learned from early closure of a clinical trial for steroid-refractory acute GVHD
38. Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease
39. Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment
40. A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
41. Germinal centre-driven maturation of B cell response to SARS-CoV-2 vaccination
42. Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia
43. Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)
44. Duvelisib for Cytokine Release Syndrome Prophylaxis during CD19-Targeted CAR T Cell Therapy
45. Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation
46. 386 - A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
47. 55 - Patient-Reported Treatment Response in Chronic Graft Vs. Host Disease: Unique Dimension of Clinical Benefit Associated with Failure-Free Survival
48. 35 - Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment
49. 34 - Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease
50. Ibrutinib for therapy of steroid-refractory chronic graft vs. host disease: A multicenter real-world analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.